Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZN002 in Mild-to-Moderate Alzheimer's Dementia
NCT05834296Phase 2Active, not recruiting
- Sponsor
- Alzamend Neuro
- Start
- Jul 2023
- Primary completion
- Mar 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ALZN002 in Alzheimer's disease (AD), sponsored by Alzamend Neuro. Started Jul 2023; status: active, not recruiting.
02
Drugs
ALZN002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05834296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834296.